Durvalumab plus chemo before surgery for upper tract cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a diagnosis of high-grade upper tract urothelial cancer (a cancer in the kidney or ureter).
- Your cancer must not have spread to other parts of the body (like lymph nodes or other organs).
- You must be in generally good health, with adequate kidney, liver, and blood cell function, and no serious, uncontrolled illnesses.
- You cannot have an active autoimmune disease or a history of certain immune-related conditions unless well-controlled.
- You should not be pregnant or breastfeeding, and must agree to use effective birth control if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests giving pembrolizumab (an immune therapy) and enfortumab vedotin (an antibody-drug medicine) before and after surgery to remove high-risk upper urinary tract cancer. The goal is to lower the chance the cancer comes back.
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
This trial tests a combination of durvalumab (an immunotherapy) with standard chemotherapy before and after bladder removal surgery for muscle-invasive bladder cancer. It aims to see if adding durvalumab helps improve outcomes while keeping side effects manageable.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery for upper tract urothelial cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Hear when a new Renal Pelvis and Ureter Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.